Company Description
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes tech...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Valuation
P/E Current
53.04
P/E Ratio (with extraordinary items)
69.31
P/E Ratio (without extraordinary items)
47.29
Price to Sales Ratio
11.39
Price to Book Ratio
11.76
Price to Cash Flow Ratio
41.97
Enterprise Value to EBITDA
37.01
Enterprise Value to Sales
11.19
Total Debt to Enterprise Value
0.01
Efficiency
Revenue/Employee
312,806.00
Income Per Employee
75,317.00
Receivables Turnover
7.65
Total Asset Turnover
0.74
Liquidity
Current Ratio
3.31
Quick Ratio
2.60
Cash Ratio
1.68
Profitability
Gross Margin
73.43
Operating Margin
27.55
Pretax Margin
26.83
Net Margin
24.08
Return on Assets
17.73
Return on Equity
28.73
Return on Total Capital
27.98
Return on Invested Capital
24.53
Capital Structure
Total Debt to Total Equity
16.36
Total Debt to Total Capital
14.06
Total Debt to Total Assets
10.46
Long-Term Debt to Equity
15.75
Long-Term Debt to Total Capital
13.53
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Michael A. Mussallem | 66 | 2000 | Chairman & Chief Executive Officer |
Mr. Scott B. Ullem | 52 | 2014 | Chief Financial Officer & Vice President |
Dr. John P. McGrath | 59 | 2006 | Vice President-Quality, Regulatory & Clinical |
Dr. Todd J. Brinton | - | 2019 | Chief Scientific Officer & VP-Advanced Technology |
Mr. Jean-Luc Lemercier | - | 2017 | Corporate Vice President |
Insider Actions
01/15/2021 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
01/15/2021 |
Michael A. Mussallem Chairman & CEO; Director |
98,550 | Derivative/Non-derivative trans. at $13.98 per share. | 1,377,729 |
01/15/2021 |
Huimin Wang CVP, Japan & Intercontinental |
11,649 | Derivative/Non-derivative trans. at $13.98 per share. | 162,853 |
01/15/2021 |
Catherine M. Szyman CVP, Critical Care |
3,389 | Derivative/Non-derivative trans. at $22.29 per share. | 75,540 |
01/15/2021 |
Michael A. Mussallem Chairman & CEO; Director |
63,242 | Disposition at $87.46 per share. | 5,531,145 |
01/15/2021 |
Michael A. Mussallem Chairman & CEO; Director |
5,308 | Disposition at $87.93 per share. | 466,732 |
01/15/2021 |
Huimin Wang CVP, Japan & Intercontinental |
11,730 | Disposition at $87.27 per share. | 1,023,677 |
01/15/2021 |
Catherine M. Szyman CVP, Critical Care |
3,389 | Disposition at $87.27 per share. | 295,758 |
01/15/2021 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
01/08/2021 |
Donald E. Bobo CVP,Strategy/Corp Development |
8,400 | Disposition at $90.22 per share. | 757,848 |
01/08/2021 |
Donald E. Bobo CVP,Strategy/Corp Development |
4,677 | Disposition at $90.85 per share. | 424,905 |
01/08/2021 |
Donald E. Bobo CVP,Strategy/Corp Development |
13,077 | Derivative/Non-derivative trans. at $13.98 per share. | 182,816 |
01/04/2021 |
Jean-Luc Lemercier CVP, EMEA, Canada, Latin Amer |
20,523 | Disposition at $91.24 per share. | 1,872,518 |
01/04/2021 |
Jean-Luc Lemercier CVP, EMEA, Canada, Latin Amer |
7,503 | Derivative/Non-derivative trans. at $11.35 per share. | 85,159 |
01/04/2021 |
Jean-Luc Lemercier CVP, EMEA, Canada, Latin Amer |
13,020 | Derivative/Non-derivative trans. at $13.98 per share. | 182,019 |
12/15/2020 |
Larry L. Wood CVP, TAVR |
9,922 | Disposition at $84.16 per share. | 835,035 |
12/15/2020 |
Larry L. Wood CVP, TAVR |
800 | Disposition at $84.83 per share. | 67,864 |
12/15/2020 |
Larry L. Wood CVP, TAVR |
10,722 | Derivative/Non-derivative trans. at $21.76 per share. | 233,310 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
34,389 | Disposition at $84.05 per share. | 2,890,395 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
33,961 | Disposition at $84.92 per share. | 2,883,968 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
200 | Disposition at $85.69 per share. | 17,138 |
12/14/2020 |
Huimin Wang CVP, Japan & Intercontinental |
11,396 | Disposition at $84.52 per share. | 963,189 |
12/14/2020 |
Huimin Wang CVP, Japan & Intercontinental |
253 | Disposition at $85.15 per share. | 21,542 |
12/14/2020 |
Huimin Wang CVP, Japan & Intercontinental |
84 | Disposition at $84.53 per share. | 7,100 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
12/14/2020 |
Michael A. Mussallem Chairman & CEO; Director |
98,550 | Derivative/Non-derivative trans. at $13.98 per share. | 1,377,729 |
12/14/2020 |
Huimin Wang CVP, Japan & Intercontinental |
11,649 | Derivative/Non-derivative trans. at $13.98 per share. | 162,853 |
12/11/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
12,774 | Disposition at $84.63 per share. | 1,081,063 |
12/11/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
300 | Disposition at $85.59 per share. | 25,677 |
12/11/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
13,074 | Derivative/Non-derivative trans. at $13.98 per share. | 182,774 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
98,550 | Derivative/Non-derivative trans. at $13.98 per share. | 1,377,729 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
35,205 | Disposition at $85.19 per share. | 2,999,113 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
30,345 | Disposition at $84.82 per share. | 2,573,862 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
2,400 | Disposition at $86.51 per share. | 207,624 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
600 | Disposition at $87.37 per share. | 52,422 |
11/17/2020 |
Michael A. Mussallem Chairman & CEO; Director |
30,000 | Gift at $0 per share. | 0 |
11/16/2020 |
Steven R. Loranger Director |
19,797 | Derivative/Non-derivative trans. at $35.2 per share. | 696,854 |
11/13/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
12,213 | Disposition at $80.52 per share. | 983,390 |
11/13/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
861 | Disposition at $81.09 per share. | 69,818 |
11/13/2020 |
Donald E. Bobo CVP,Strategy/Corp Development |
13,074 | Derivative/Non-derivative trans. at $13.98 per share. | 182,774 |
11/11/2020 |
Huimin Wang CVP, Japan & Intercontinental |
8,290 | Disposition at $81.01 per share. | 671,572 |
11/11/2020 |
Huimin Wang CVP, Japan & Intercontinental |
3,359 | Disposition at $81.76 per share. | 274,631 |
11/11/2020 |
Huimin Wang CVP, Japan & Intercontinental |
81 | Disposition at $81.76 per share. | 6,622 |
11/11/2020 |
Huimin Wang CVP, Japan & Intercontinental |
11,649 | Derivative/Non-derivative trans. at $13.98 per share. | 162,853 |
MarketWatch News on EW
-
Edwards Lifesciences Corp. stock falls Friday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences stock price target raised to $100 vs. $95 at Stifel
- Ciara Linnane
-
Edwards Lifesciences Corp. stock price target raised to $96 vs. $90 at Raymond James
- Ciara Linnane
-
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Thursday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Monday, still underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock falls Friday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock remains steady Thursday, underperforms market
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Edwards Lifesciences Corp. stock rises Monday, still underperforms market
- MarketWatch Automation
- Loading more headlines...
Other News on EW
-
Wedgewood Partners Q4 2020 Client Letter
- Seeking Alpha
-
Bear of the Day: Penumbra (PEN)
- Zacks.com
-
A Quality Stock Index That Consistently Outperforms The Market
- Seeking Alpha
-
Expanded use of Edwards' Sapien 3 valve OK'd in Canada
- Seeking Alpha
-
Edwards Lifesciences (EW) Gets a Hold Rating from BTIG
- SmarterAnalyst
-
7 ESG Investing Ideas That Could Add to Your Wallet and to Your Soul
- InvestorPlace.com
-
Oppenheimer Believes Edwards Lifesciences (EW) Won’t Stop Here
- SmarterAnalyst
-
3 Strong, Margin-Expanding Stocks
- GuruFocus.com
-
Healthcare rallies as Presidential vote count continues
- Seeking Alpha
-
The CVP, Critical Care of Edwards Lifesciences is Exercising Options
- SmarterAnalyst
- Loading more headlines...